Platelet membrane-camouflaged nanoparticles carry microRNA inhibitor against myocardial ischaemia‒reperfusion injury

Wang, Tianyi; Zhou, Tingting; Xu, Mingming; Wang, Shuo; Wu, Anqi; Zhang, Mingyang; Zhou, You Lang; Shi, Jiahai

doi:10.1186/s12951-022-01639-8

Cited by 26 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[100] Inspired by the cardioprotective ability of Nrf2 during MIRI, Wang et al identified miR-155-5p, a microRNA that effectively regulates Nrf2 and mediates MIRI, and formulated PNPs containing inhibitors of miR-155-5p for the treatment of MIRI. [101] The researchers encapsulated miR-155-5p inhibitors within PLGA NPs using a double emulsion technique known for its high transfection efficiency. Subsequently, the resulting PNPs were coated with PM using ultrasound.…”

Section: Cardiovascular Diseasementioning

confidence: 99%

Biomedical Applications of Cell Membrane‐Based Biomimetic Nano‐Delivery System

Zhang,

Wang,

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Surface modification of nanoparticles (NPs) is crucial for their effective utilization in diverse medical conditions, as it addresses challenges such as rapid passive clearance by the immune system, damage to the reticuloendothelial system, lack of specific cell targeting, and inadequate biocompatibility. The natural cell membrane (CM)‐coating technology has recently garnered considerable attention as an optimal strategy for enhancing artificial nanoformulations. This biomimetic technique directly confers inner NPs with multiple functions, such as immune evasion, precise targeting, and excellent biocompatibility, all of which are mediated by source cell‐inherent surface membrane proteins. Additionally, engineering techniques originally designed to enhance existing theranostic modalities employed in clinical settings are applied to natural CM carriers, thereby improving the physical properties of nanomaterials to drive further advancements. In this comprehensive review, diverse CM sources, such as red blood cells, platelets, white blood cells, cancer cells, bacteria, and other unconventional types, the core NPs employed in these cell membrane‐coated nanoparticles (CM‐NPs), preparation methods, and the latest advancements of CM‐NPs across diverse biomedical fields, are reviewed. Engineering strategies for enhancing natural CMs have also been emphasized. Furthermore, the review comprehensively addresses the major challenges and their corresponding solutions in the clinical translation of this evolving field.

show abstract

Section: Cardiovascular Diseasementioning

confidence: 99%

Biomedical Applications of Cell Membrane‐Based Biomimetic Nano‐Delivery System

Zhang,

Wang,

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…[ 14 ] Under physiological conditions, Nrf2 plays an important role in reducing oxidative stress, endoplasmic reticulum stress, and mitochondrial repair, reducing inflammation and autophagy, and protecting cardiomyocytes during MIRI. [ 15 ] Interestingly, two potential targets of Nrf2 inactivation that may cause ferroptosis, xCT and glutathione peroxidase 4 (GPX4), are well confirmed to be controlled by Nrf2. [ 16 ] The level of Nrf2 has been correlated with ferroptosis sensitivity because Nrf2‐downregulated cancer cells are susceptible to ferroptosis‐promoting drugs, and the occurrence and execution of ferroptosis could be prevented by overexpression of Nrf2.…”

Section: Introductionmentioning

confidence: 99%

Tempol alleviates acute lung injury by affecting glutathione synthesis through Nrf2 and inhibiting ferroptosis in lung epithelial cells

Ai,

Li,

Wang

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

As a life‐threatening disease, acute lung injury (ALI) may progress to chronic pulmonary fibrosis. For the treatment of lung injury, Tempol is a superoxide dismutase mimetic and intracellular redox agent that can be a potential drug. This study investigated the regulatory mechanism of Tempol in the treatment of ALI. A mouse model of ALI was established, and HE staining was used to examine histomorphology. The CCK‐8 assay was used to measure cell viability, and oxidative stress was assessed by corresponding kits. Flow cytometry and dichlorodihydrofluorescein diacetate staining assays were used to detect reactive oxygen species (ROS) levels. Protein expression levels were measured by Western blot analysis and ELISA. Pulmonary vascular permeability was used to measure the lung wet/dry weight ratio. The level of oxidative stress was increased in ALI mice, and the level of ferroptosis was upregulated. Tempol inhibited this effect and alleviated ALI. The administration of Tempol alleviated the pathological changes in ALI, inhibited pulmonary vascular permeability, and improved lung injury in ALI mice. The upregulation of genes essential for glutathione (GSH) metabolism induced by lipopolysaccharide (LPS) was inhibited by Tempol. In addition, nuclear factor‐related factor 2 (Nrf2) is activated by Tempol therapy to regulate the de novo synthesis pathway of GSH, thereby alleviating LPS‐induced lung epithelial cell damage. The results showed that Tempol alleviated ALI by activating the Nrf2 pathway to inhibit oxidative stress and ferroptosis in lung epithelial cells. In conclusion, this study demonstrates that Tempol alleviates ALI by inhibiting ferroptosis in lung epithelial cells through the effect of Nrf2 on GSH synthesis.

show abstract

“…19 These widespread applications are attributed to their outstanding properties such as prolonged circulation, immune evasion, and targeting capability. 20 Red blood cell membrane-coated nanoparticles (RBCNPs) were the first platform to be employed, 21 followed by platelets, 22 tumor cells, 23 and macrophages. 24 These bionic NPs retain the biological function of the source cells.…”

Section: Introductionmentioning

confidence: 99%